Propofol inhibits the growth and survival of gastric cancer cells in vitro through the upregulation of ING3

Abstract

Propofol is one of the most extensively used intravenous anesthetic agents and it can influence the biological behavior of gastric cancer. However, the underlying mechanism is poorly understood. In the present study, we found that propofol significantly inhibited cell proliferation, invasion and migration, and also promoted apoptosis in gastric carcinoma cell lines SGC-7901 and MGC-803, as detected using MTT, colony formation and flow cytometry assays, respectively. Moreover, propofol (10 and 20 µM) markedly upregulated the expression of inhibitor of growth 3 (ING3), which was lower in SGC-7901 and MGC-803 cells compared with that noted in normal human gastric epithelial cell lines GES-1 and HFE145. Furthermore, we transfected SGC-7901 and MGC-803 cells with ING3 overexpression vectors or ING3 small interference RNA (siING3), respectively, to assess the role of ING3 in propofol-induced antitumor activity. The siING3 transfection reversed the effects of propofol on the biological behavior of gastric cancer cells, while transfection of ING3 promoted the effects of propofol. In conclusion, our results indicate that propofol exerts an inhibitory effect on the growth and survival of gastric cancer cells by interfering with ING3 degradation.

Propofol inhibits pancreatic cancer progress under hypoxia via ADAM8

“…Yang et al. provided evidence that propofol inhibited the growth and survival of gastric cancer cells in vitro through the up‐regulation of ING3. Tan et al.…”

Propofol inhibits Wnt signaling and exerts anticancer activity in glioma cells

“…In addition to its anesthetic advantages, accumulating clinical evidence demonstrates that cancer patients receiving propofol-paravertebral anesthesia during cancer surgery have reduced risk of recurrence and metastasis (19). In addition, studies have shown that propofol exhibits potent antitumor activity in a variety of human cancer cell lines, including lung cancer cells (20), colon carcinoma cells (21), cervical cancer cells (22), pancreatic cancer cells (23) and gastric cancer cells (24), through different molecular mechanisms. However, the effect of propofol on Wnt signaling and glioma cell growth remains to be elucidated.…”

Effect of volatile and intravenous anesthesia on long-term survival of cancer surgery patients: a systematic review and meta-analysis

“…It can extract on lymphocytes apoptosis inducton, natural killer (NK) cytotoxicity inhibition and cytokines release alteration by NK cells in response to malignant cells, ultimately contributing to the development of migration and recurrence postoperatively [35]. However, as the most popular and common choice in TIVA, propofol has been considered to have predominately anticancer effects [10][11][12][13]. It can boost immune functions of the body and thus inhibit the cancer spread and metastasis [10][11][12][13].…”

“…However, as the most popular and common choice in TIVA, propofol has been considered to have predominately anticancer effects [10][11][12][13]. It can boost immune functions of the body and thus inhibit the cancer spread and metastasis [10][11][12][13]. Especially, propofol infusion anaesthesia has been found to modulate the Th1/ 2 balance by increasing the IFN-γ/IL-4 ratio in vitro [34].…”

“…It is shown that inhalation agents appear to have the proinflammatory effect and to alter the immune processes, thereby on the one hand promoting the metastasis of lung and breast cancer in mice and humans [8][9]. But on the other hand, propofol has been demonstrated to exert predominately anticancer properties through multiple mechanisms, such as through suppression of the vascular proliferation and regeneration associated with surgery, anti-inflammatory and antioxidative activities and so on [10][11][12][13]. These mechanisms all lead to the notion that the administration of inhalation agent in surgery may facilitate cancer prognosis while propofol has a beneficial effect.…”